 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
September 19, 2012
MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
December 19, 2012 / Pharmacogenomics Reporter - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 1, 2012 / Pharmacogenomics Reporter - Ariad Advances Drug for Resistant Leukemia Patients with MolecularMD's Companion Test
March 30, 2011 / Pharmacogenomics Reporter - Medco to Expand PGx Offerings to All Clients in July
May 26, 2010 / Pharmacogenomics Reporter